New ISR Report Offers Visibility Into CRO Service Quality for Phase I Clinical Trials
Informing the Drug Development and Commercialization Industry
(firmenpresse) - CARY, NC -- (Marketwired) -- 08/23/13 -- (ISR) today announced the availability of a new report titled "" providing the most comprehensive assessment of Phase I clinical research organization (CRO) service quality ever released.
"ISR's report provides unique visibility into how pharmaceutical and biotech companies outsource Phase I trial activities, as well as insight into the service quality of 22 Phase I CROs," explained Kevin Olson, CEO of ISR. "With this type of market intelligence, study sponsors can arm themselves with data to empower decision-making and selection of service providers."
ISR's report compiles data from respondents who were asked to rate their service experiences with CROs they have used within the past 18 months. Respondents were given 28 different service attributes to consider, including the CRO's ability to Access Patient Populations, Minimize Change Orders, Meet Overall Project Timelines, and many others.
Data include service encounter analyses for 22 Phase I CROs, including: CEDRA, Celerion, Charles River, Chiltern, Covance, DaVita, DCRI-Duke, ICON, INC Research, InVentiv Health Clinical, Medpace, PAREXEL, PPD, PRA, Premier Research, Quintiles, Rho, SGS Life Sciences, Siro Clinpharm, Theorem, US Oncology, and WCCT Global.
What were the results of ISR's survey? Olson emphasized one interesting trend in attribute ratings across service providers.
"While analyzing data from 360 unique service experiences, we were able to uncover several attributes where delivery is consistently positive across providers and other attributes where provider performance is more differentiated," Olson explained. "One attribute where most Phase I CROs meet expectations is Scientific Knowledge, while much more variability exists in Low Cost and Data Quality, to name just two."
For more information on ISR's "2013 CRO Quality Benchmarking - Phase I Service Providers" report, please visit ISR's report page at .
For more information on ISR's Phase II/III and Phase IV CRO Quality Benchmarking reports, you may visit ISR's website at .
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR's off-the-shelf intelligence and custom research offerings, please visit the company's Web site at , email , or follow ISR on Twitter .
Image Available:
Kevin Olson
+1 919 301 0106
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.08.2013 - 14:25 Uhr
Sprache: Deutsch
News-ID 290491
Anzahl Zeichen: 0
contact information:
Town:
CARY, NC
Kategorie:
Information Services
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New ISR Report Offers Visibility Into CRO Service Quality for Phase I Clinical Trials"
steht unter der journalistisch-redaktionellen Verantwortung von
Industry Standard Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
